TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06922591: Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Sponsor: Tango Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 183 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT06922591 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06922591 Rescue Dossier →